

**JULY 2026 PBAC MEETING – CONSIDERATION OF THE REPORT OF THE
DRUG UTILISATION SUB-COMMITTEE**

**PBAC CONSIDERATION OF THE REPORT OF THE
DRUG UTILISATION SUB-COMMITTEE**

The PBAC noted reports with associated stakeholder responses from the June 2026 Drug Utilisation Sub-Committee (DUSC) meeting, which were provided in items 10.03, 10.04, and 10.05 of the PBAC Agenda. DUSC minutes relating to these items were provided to the PBAC. The outcomes of the DUSC consideration of these items are available in the [June 2026 DUSC outcome statement](#).

**PEMBROLIZUMAB FOR STAGE II OR STAGE III AND RECURRENT,
UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER**

Outcome

The PBAC noted that the uptake of pembrolizumab for both recurrent, unresectable or metastatic (metastatic) triple negative breast cancer (mTNBC) and stage II or stage III (early-stage) triple negative breast cancer (eTNBC) had plateaued.

The PBAC noted that the introduction of olaparib for both eTNBC and mTNBC has not had an appreciable impact on pembrolizumab treatment rates for either eTNBC or mTNBC.

**ANTIVIRALS FOR THE TREATMENT OF SEVERE-ACUTE-RESPIRATORY
SYNDROME CORONAVIRUS-2 (SARS-COV-2) INFECTION**

Outcome

The PBAC noted the overall utilisation of COVID-19 oral antivirals has been decreasing. The PBAC noted molnupiravir has accounted for most of the COVID-19 oral antiviral market.

The PBAC noted among the population groups eligible for COVID-19 oral antiviral treatment, patients aged 70 years and older account for the majority of utilisation.

**ENFORTUMAB VEDOTIN FOR LOCALLY ADVANCED (STAGE III) OR
METASTATIC (STAGE IV) UROTHELIAL CANCER**

Outcome

The PBAC noted the number of treated patients and prescriptions supplied have plateaued.

The PBAC noted the patient demographics appear to match epidemiology of urothelial cancer, with median age of patients initiating treatment of 71 years and males accounting for the majority of utilisation.